Li, 103 patient convalescent plasma late treatment RCT: 35% lower mortality [p=0.3], 15% better improvement [p=0.37], and 76% improved viral clearance [p=0.01] https://c19p.org/li8
copied to clipboard
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial
et al., JAMA, doi:10.1001/jama.2020.10044
Small RCT 103 severe condition patients, 52 treated with convalescent plasma, showing improved viral clearance but no statistically significant improvements in mortality or clinical improvement. ChiCTR2000029757.
|
risk of death, 34.6% lower, RR 0.65, p = 0.30, treatment 8 of 51 (15.7%), control 12 of 50 (24.0%), NNT 12, odds ratio converted to relative risk, 28 days.
|
|
risk of no improvement, 15.3% lower, RR 0.85, p = 0.37, treatment 25 of 52 (48.1%), control 29 of 51 (56.9%), NNT 11, odds ratio converted to relative risk, 28 days.
|
|
risk of no viral clearance, 76.4% lower, RR 0.24, p = 0.01, treatment 4 of 26 (15.4%), control 15 of 23 (65.2%), NNT 2.0, odds ratio converted to relative risk.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Li et al., 6/3/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 34 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.